2023-2028 Asia-Pacific Virology, Bacteriology, Parasitology and Mycology Testing Market in 18 Countries-2023 Supplier Shares by Test, 2023-2028 Centralized and POC Volume and Sales Forecasts for 100 Respiratory, STD, Enteric, and other Microbiology Assays Performed in Hospitals, Commercial/Private Labs, POC Locations-Competitive Strategies and SWOT Analysis, Latest Technologies, Instrumentation Pipeline, Market Barriers and Risks
This new report from LeadingMarketResearch.com provides data and analysis not available from any other published source. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.
The report provides granular market segmentation analysis and forecasts for over 100 microbiology tests; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and strategies for suppliers.
Rationale
This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.
The infectious disease testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces are advances in molecular diagnostic technologies; threat of bioterrorism; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Infectious Diseases Analyzed in the Report
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Carbapenemase, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes, Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, Norovirus, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Country Analyses
Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Turkey, Vietnam
Market Segmentation Analysis
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
Opportunities and Strategies for Suppliers
The report provides granular market segmentation analysis and forecasts for over 100 microbiology tests; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and strategies for suppliers.
Rationale
This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding infectious disease testing market, in evaluating emerging opportunities and developing effective business strategies.
The infectious disease testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces are advances in molecular diagnostic technologies; threat of bioterrorism; and a wider availability of immunosuppressive drugs. Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.
Infectious Diseases Analyzed in the Report
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Carbapenemase, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes, Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, Norovirus, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus , Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
Country Analyses
Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Turkey, Vietnam
Market Segmentation Analysis
- Sales and market shares of major suppliers of infectious disease diagnostic products in major countries by test.
- Test and sales forecasts for 100 infectious disease diagnostic assays by country, individual test and market segment:
- Review of market dynamics, trends, structure, size, growth and major suppliers.
- In-depth examination of major diseases, including their etiology, current diagnostic tests, vaccines, drugs and market needs.
- Review of major analyzers used for infectious disease testing, including their operating characteristics, features and selling prices.
- Assessment of emerging diagnostic technologies and their potential applications for infectious disease testing.
- Companies developing or marketing infectious disease diagnostic products by individual test.
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.
Opportunities and Strategies for Suppliers
- Emerging opportunities for new instrumentation, reagent systems, IT and other products with significant market appeal during the next five years.
- Design criteria for decentralized testing products.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.
I. INTRODUCTION
II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
IV. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. OVERVIEW OF MAJOR TESTS, TECHNOLOGIES AND INSTRUMENTATION
A. Major Infectious Disease Tests
1. AIDS: HIV/HIV-1/2/Combo, HIVAg/HIV NAT, Western Blot, HTLV-I/II
2. Adenovirus
3. Aeromonas
4. Anthrax/Bacillus Anthracis
5. Arboviruses
6. Babesiosis
7. Bacillary Epithelioid Angiomatosis (BEA) and Other Bartonella (Rochalimaea)
8. Blastocystis Hominis
9. Brucella
10. Campylobacter
11. Candida
12. Carbapenemase
13. Chagas Disease
14. Chancroid
15. Chlamydia
16. Clostridium Difficile
17. Coronaviruses
18. Coxsackieviruses
19. Creutzfeldt-Jakob’s Disease
20. Cryptosporidium Parvum
21. Cyclospora Cayetanensis
22. Cytomegalovirus
23. Ebola Virus
24. E. Coli
25. Echovirus
26. Encephalitis
27. Enteroviruses
28. Epstein-Barr Virus
30. Giardia Lamblia
31. Gonorrhea
32. Granuloma Inguinale
33. Hantavirus
34. Helicobacter Pylori
35. Hepatitis: HAV NAT, HBV NAT, HBs Ag, HCV, HCV NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, ALT/SGPT
36. Herpes Simplex Virus
37. Human Herpes Virus-6 (HHV-6)
38. Influenza Viruses
39. Legionella
40. Lyme Disease
41. Lymphogranuloma Venereum (LGV)
42. Malaria
43. Measles (Rubeola)
44. Meningitis
45. Microsporidium
46. Mononucleosis
47. Mumps
48. Mycoplasma
49. Norovirus
50. Papillomaviruses
51. Parvovirus B19
52. Pneumonia
53. Polyomaviruses
54. Pseudomonas Aeruginosa
55. Rabies
56. Respiratory Syncytial Virus (RSV)
57. Rhinoviruses
58. Rotavirus
59. Rubella
60. Salmonellosis
61. Septicemia
62. Shigellosis
63. Staphylococcus Aureus
64. Streptococci
65. Syphilis
66. Toxoplasmosis
67. Trichomonas Vaginalis
68. Tuberculosis
69. Vibrio
70. West Nile Virus
71. Yersina
B. Instrumentation Review: Operating Characteristics, Features and Selling Princes of Leading Infectious Disease Automated and Semi-automated Analyzers
C. Emerging Infectious Disease Diagnostic Technologies
1. Molecular Diagnostics
2. Monoclonal Antibodies
3. Immunoassays
4. Differential Light Scattering
5. Information Technology
6. Artificial Intelligence
7. Liposomes
8. Flow Cytometry
9. Chromatography
10. Diagnostic Imaging
11. Gel Microdroplets
12. Others
D. Personal Testing
VII. COUNTRY ANALYSES: SALES AND VOLUME FORECASTS FOR 100 MICROBIOLOGY TESTS, SUPPLIER SHARES
Australia
Bangladesh
China
Hong Kong
India
Indonesia
Japan
Malaysia
Myanmar
New Zealand
Pakistan
Philippines
Singapore
South Korea
Taiwan
Thailand
Turkey
Venezuela
Vietnam
VIII. COMPETITIVE ASSESSMENTS
Abbott
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Decode Genetics
Eiken Chemical
Elitech Group
Enzo Biochem
Exact Sciences
Fujifilm Wako
Fujirebio
Grifols
Hologic
Illumina
Leica Biosystems
Li-Cor Biosciences
Myriad Genetics
PerkinElmer
Proteome Sciences
Qiagen
Quest Diagnostics
QuidelOrtho
Roche
Scienion
Sequenom/LabCorp
Shimadzu
Siemens Healthineers
Sierra Molecular
Takara Bio
Tecan Group
Thermo Fisher
II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES
A. Instrumentation
B. Reagent Kits and Test Systems/Panels
C. Information Technology
D. Auxiliary Products
III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS
IV. ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
VI. OVERVIEW OF MAJOR TESTS, TECHNOLOGIES AND INSTRUMENTATION
A. Major Infectious Disease Tests
1. AIDS: HIV/HIV-1/2/Combo, HIVAg/HIV NAT, Western Blot, HTLV-I/II
2. Adenovirus
3. Aeromonas
4. Anthrax/Bacillus Anthracis
5. Arboviruses
6. Babesiosis
7. Bacillary Epithelioid Angiomatosis (BEA) and Other Bartonella (Rochalimaea)
8. Blastocystis Hominis
9. Brucella
10. Campylobacter
11. Candida
12. Carbapenemase
13. Chagas Disease
14. Chancroid
15. Chlamydia
16. Clostridium Difficile
17. Coronaviruses
18. Coxsackieviruses
19. Creutzfeldt-Jakob’s Disease
20. Cryptosporidium Parvum
21. Cyclospora Cayetanensis
22. Cytomegalovirus
23. Ebola Virus
24. E. Coli
25. Echovirus
26. Encephalitis
27. Enteroviruses
28. Epstein-Barr Virus
30. Giardia Lamblia
31. Gonorrhea
32. Granuloma Inguinale
33. Hantavirus
34. Helicobacter Pylori
35. Hepatitis: HAV NAT, HBV NAT, HBs Ag, HCV, HCV NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, ALT/SGPT
36. Herpes Simplex Virus
37. Human Herpes Virus-6 (HHV-6)
38. Influenza Viruses
39. Legionella
40. Lyme Disease
41. Lymphogranuloma Venereum (LGV)
42. Malaria
43. Measles (Rubeola)
44. Meningitis
45. Microsporidium
46. Mononucleosis
47. Mumps
48. Mycoplasma
49. Norovirus
50. Papillomaviruses
51. Parvovirus B19
52. Pneumonia
53. Polyomaviruses
54. Pseudomonas Aeruginosa
55. Rabies
56. Respiratory Syncytial Virus (RSV)
57. Rhinoviruses
58. Rotavirus
59. Rubella
60. Salmonellosis
61. Septicemia
62. Shigellosis
63. Staphylococcus Aureus
64. Streptococci
65. Syphilis
66. Toxoplasmosis
67. Trichomonas Vaginalis
68. Tuberculosis
69. Vibrio
70. West Nile Virus
71. Yersina
B. Instrumentation Review: Operating Characteristics, Features and Selling Princes of Leading Infectious Disease Automated and Semi-automated Analyzers
C. Emerging Infectious Disease Diagnostic Technologies
1. Molecular Diagnostics
2. Monoclonal Antibodies
3. Immunoassays
4. Differential Light Scattering
5. Information Technology
6. Artificial Intelligence
7. Liposomes
8. Flow Cytometry
9. Chromatography
10. Diagnostic Imaging
11. Gel Microdroplets
12. Others
D. Personal Testing
VII. COUNTRY ANALYSES: SALES AND VOLUME FORECASTS FOR 100 MICROBIOLOGY TESTS, SUPPLIER SHARES
Australia
Bangladesh
China
Hong Kong
India
Indonesia
Japan
Malaysia
Myanmar
New Zealand
Pakistan
Philippines
Singapore
South Korea
Taiwan
Thailand
Turkey
Venezuela
Vietnam
VIII. COMPETITIVE ASSESSMENTS
Abbott
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biokit
bioMerieux
Bio-Rad
Decode Genetics
Eiken Chemical
Elitech Group
Enzo Biochem
Exact Sciences
Fujifilm Wako
Fujirebio
Grifols
Hologic
Illumina
Leica Biosystems
Li-Cor Biosciences
Myriad Genetics
PerkinElmer
Proteome Sciences
Qiagen
Quest Diagnostics
QuidelOrtho
Roche
Scienion
Sequenom/LabCorp
Shimadzu
Siemens Healthineers
Sierra Molecular
Takara Bio
Tecan Group
Thermo Fisher
